Matthew Holdren, Ph.D., DABT

Matthew Holdren, Ph.D. serves as Vice President, Head of Nonclinical Development at Lycia. He has extensive expertise in drug development across a range of therapeutic modalities and disease areas, with a proven track record of success in pharmaceutical R&D. At Lycia, Matt leads drug development efforts and is focused on the strategy and operational components of bringing our novel molecules into clinical development. Prior to joining Lycia, Matt was Head of Nonclinical Development at Tenaya Therapeutics, Senior Director of Safety Assessment at Genentech, and Project Toxicologist at Bristol-Myers Squibb/ZymoGenetics. He is a modality-agnostic leader in nonclinical development and has had the privilege to work with multiple teams from early discovery through clinical development. Matt obtained his undergraduate degree in Microbiology and Ph.D. in Pathology from the University of Washington and is a long-standing Diplomat of the American Board of Toxicology.